@BiVictriXTherapeutics

Exploiting the Bi-Cygni technology, delivering a new class of biotherapeutics with superior selectivity.

[@BiVictriXTherapeutics @BiVictriX]

These compelling results demonstrate the potential of BVX002 to deliver meaningful efficacy where other B7-H4-targeted ADCs fall short. To read more about this study, visit our website.

[@BiVictriXTherapeutics @BiVictriX]

🚀 Exciting news from BiVictriX! Our lead solid‑tumour ADC, BVX002, has delivered tumour growth inhibition and regressions in an AZD8205-resistant mouse 🎯

New data shows that a single dose of BVX002 reverses tumour growth in an AZD8205-resistant mouse 🌟

[@BiVictriXTherapeutics @BiVictriX]

In a mouse unresponsive to AstraZeneca’s B7H4-TOPOi-based ADC, AZD8205, a single dose of BVX002 was not only able to reverse the exponential growth of the tumour but also resulted in tumour regressions of >62% in just 14 days!

[@BiVictriXTherapeutics @BiVictriX]

🔗 Read the full press release for the data & context:

https://t.co/GJlFm1fm7n

#Oncology #Biotech #PharmaInnovation #BispecificADC

[@BiVictriXTherapeutics @BiVictriX]

🚀 Preclinical win for #BiVictriX: Our bispecific ADC, BVX002, outperformed 2 B7H4-targeted competitors (Pfizer’s SGN-B7H4V* & AZ’s AZD8205*) in head-to-head studies.

📊 Tumor regressions across all doses tested.

👇 More on why this matters:

[@BiVictriXTherapeutics @BiVictriX]

✅ Our Bi-Cygni® platform breaks through expression thresholds that limit conventional ADCs.

🧬 Precision, potency, and consistent DAR4 from our site-specific conjugation tech.

We’re setting a new bar in #ADC innovation.

[@BiVictriXTherapeutics @BiVictriX]

🔬 At BiVictriX, we’re not confined to 1 ADC design philosophy. Our BVX002 programme employs an innovative “AND/OR���-gated bispecific ADC to tackle ovarian cancer's tumour heterogeneity. It’s about clinically relevant solutions, not just being different. #ADC #bispecific #oncology

[@BiVictriXTherapeutics @BiVictriX]

We’ve got MORE exciting data to share with you! 🚨

Our latest pre-clinical study found that BVX001 increased survival rates in acute myeloid leukaemia (AML) by 126% compared to an untreated control group.

Find out more: https://t.co/dk065WMOq4

#AML #BloodCancer #antibodies

[Proactive @proactive_x]

$BVX Bivictrix Therapeutics progress attracting interest, says CEO https://t.co/HzUAhy2Ubr @bivictrix $BVTXF #BVX #BVTXF

[@BiVictriXTherapeutics @BiVictriX]

We're pleased to announce our lead asset, BVX001, has been granted a US patent!

This is a big step on BiVictriX's journey, providing broad protection for our lead therapeutic asset at the antigen level.

Find out more: https://t.co/LiDtuevETV
#bloodcancer #AML #ADC #biotech

[@BiVictriXTherapeutics @BiVictriX]

Is the accepted dogma around the therapeutic window of #ADCs in need of a rethink?

In their recent paper, Columbo and Rich highlight the mounting clinical evidence that suggests ADCs do not significantly increase the MTD of their conjugated drugs: https://t.co/E19nzlOlc4

[@BiVictriXTherapeutics @BiVictriX]

Discover how our clinical lead candidate, BVX001, addresses some of the shortcomings of current antibody drug conjugate (ADC) treatments for acute myeloid leukaemia in this in-depth article in @Labiotech_eu https://t.co/X2mkBT88gS #ADC #AML #pipeline #biotech

[LUKA GLOBAL GROUP @lukaglobal]

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine - https://t.co/CYS2QJz1RU

[Proactive @proactive_x]

$BVX BiVictriX sees positive final data in BVX001 leukaemia drug study https://t.co/Uv6pRhS0sz @bivictrix $BVTXF #BVX #BVTXF

[@BiVictriXTherapeutics @BiVictriX]

We’re delighted to share positive final data in the preclinical efficacy study of BVX001, our lead Bi-Cygni® bi-specific ADC for AML. Find out more: https://t.co/0bwhGyN4UA #ADC #AML #pipeline #Drugdevelopment

[@BiVictriXTherapeutics @BiVictriX]

With Cancer Immunotherapy Month coming to an end, we wanted to highlight another way we are contributing to the development of high-impact cancer therapies. Discover more about our science and pipeline: https://t.co/5brMM5RWwV #CIM23 #Immune2Cancer #immunotherapy

[@BiVictriXTherapeutics @BiVictriX]

We’re excited to reveal the positive interim data from our second preclinical efficacy study of BVX001 — our lead ADC programme for AML - in larger tumours. Read more: https://t.co/L6sWbda7PY

#ADC #AML #Biotech #pipeline #antibodytherapeutics #oncology #drugdevelopment

[Proactive @proactive_x]

$BVX BiVictriX Therapeutics data underscores the potential of leukemia drug https://t.co/ho4u7OiVUZ @bivictrix $BVTXF #BVX #BVTXF

[Proactive @proactive_x]

$BVX BiVictriX Therapeutics shares close 7% higher after making preclinical progress https://t.co/B3IwQ3FAIO @bivictrix $BVTXF #BVX #BVTXF